A Phase 2 interventional study of Standard Western medicine treatment + Chaigui Longmu Ejiao Paste and Placebo Comparator: Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao in Ischemic Heart Disease, sponsored by Longhua Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Longhua Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Myocardial Ischemia with a site in China — 20 open to participants now, 22 under way, none of them phase 3. Myocardial Ischemia · China.
Among the 81 studies in Myocardial Ischemia with a site in China, this one is the 36th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 2, reaches primary completion later than 11 of the 21 other live ones, and was the 77th registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →20 of the 81 studies in Myocardial Ischemia with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Shanghai East Hospital · Sites in China
Ages up to 80
Qilu Hospital of Shandong University · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 3 · Phase 4 12
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 303 across the 48 interventional studies, 400 across the 33 observational. Of the 39 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 81 have an industry lead sponsor. The 10 most frequent:
Longhua Hospital is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Longhua Hospital has 1 study filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Ischemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05891145Yangzhou UniversityRemimazolam for Postoperative Atrial Fibrillation | 2026-12 |
| NCT07478328Longhua HospitalChaigui Longmu Ejiao Paste for Ischemic Heart Disease | 2027-03-31 |
| NCT07100457Southeast University, ChinaOR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury | 2027-08-30 |
| NCT07912801Peking University First HospitalRoxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Myocardial Ischemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study explores whether Chaigui Longmu Ejiao Paste can reduce the average weekly number of angina attacks in patients with ischemic heart disease after 8 weeks of treatment, using Chaigui Longmu Paste without Ejiao as a parallel control and incorporating a synthesized external control.
Overall Study Design: This is a randomized, double-blind clinical trial with internal and external controls.
Trial Procedure: The study includes a screening/baseline period, an 8-week treatment period, and a 4-week follow-up period. The end-of-study/end-of-treatment visit (EOS/EOT) is performed at 12 weeks after treatment initiation.
Randomization and Blinding: Block randomization is applied, with a 1:1 allocation ratio across groups. The trial is double-blinded.
External Control: Literature data (external control derived from published literature).
Data Collection: Data are collected using an Electronic Data Capture (EDC) system in combination with an electronic Patient-Reported Outcomes (ePRO) system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients receive standard Western medical treatment prescribed by the attending physician in accordance with the latest clinical guidelines, including but not limited to antiplatelet agents, statins, β-blockers, ACE inhibitors/ARBs, and others. Participants in the experimental arm received Chaigui Longmu Ejiao Paste 15 g orally twice daily (morning and evening) for 8 weeks.
Drug: Standard Western medicine treatment + Chaigui Longmu Ejiao Paste
All patients receive standard Western medical treatment prescribed by the attending physician in accordance with the latest clinical guidelines, including but not limited to antiplatelet agents, statins, β-blockers, ACE inhibitors/ARBs, and others. Participants received Chaigui Longmu Paste without Ejiao 15 g orally twice daily (morning and evening) for 8 weeks.
Drug: Placebo Comparator: Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao
15 g orally twice daily
15 g orally twice daily
Average weekly reduction in angina attack frequency
The mean change in the average number of angina attacks per week from baseline to the end of the 8-week treatment period in patients with ischemic heart disease ; Recorded using electronic patient-reported outcomes (ePRO).
Time frame: Baseline to week 8
Change from Baseline in Seattle Angina Questionnaire (SAQ) Scores
The Seattle Angina Questionnaire (SAQ) is a validated, disease-specific, self-reported instrument that assesses health status in patients with angina due to ischemic heart disease. It measures five domains: Physical Limitation (extent of limitation in physical activity due to angina), Angina Stability (change in angina frequency over the past 4 weeks), Angina Frequency (frequency and burden of angina episodes), Treatment Satisfaction (satisfaction with angina treatment), and Disease Perception/Quality of Life (impact of angina on quality of life). Each domain is scored from 0 to 100, with higher scores indicating better health status (less limitation, fewer symptoms, greater satisfaction, better quality of life). Change = (Week 4 or Week 8 Score - Baseline Score) for each domain and the total score (overall summary score, if applicable, averaging the relevant domains).
Time frame: Baseline, Week 4, and Week 8
Average Weekly Nitroglycerin Consumption
The average number of nitroglycerin tablets (or sublingual sprays) used per week by the participant to relieve angina symptoms. This is a key indicator of angina burden and rescue medication requirement.
Time frame: Week 4, and Week 8
Change from Baseline in Traditional Chinese Medicine (TCM) Syndrome Score
The TCM Syndrome Score is a composite system based on the diagnostic criteria for the pattern "Chest Yang Deficiency with Heart Vessel Stasis". It assesses severity of: * Primary symptoms (chest oppression/chest pain, palpitations) * Secondary symptoms (insomnia, aversion to cold, spontaneous sweating, irritability/restlessness of heart and mind) Tongue and pulse are observed but not scored numerically. Scoring: * Primary symptoms: 0 (absent), 2 (mild), 4 (moderate), 6 (severe) * Secondary symptoms: 0 (absent), 1 (mild), 2 (moderate), 3 (severe) Total score = sum of all symptom scores. Higher score = greater severity. Change value * score at week 4 or 8 - baseline score A lower (more negative) change value indicates greater improvement in the TCM syndrome.
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered, 14-item instrument that assesses the severity of anxiety symptoms. Each item is scored from 0 (none) to 4 (severe), with a total score ranging from 0 to 56 (higher scores indicate greater anxiety severity). The scale are administered by trained clinicians. Change = (Week 4 or Week 8 total score - Baseline total score) for each scale. Negative changes indicate improvement (reduction) in anxiety symptoms.
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Hamilton Depression Rating Scale (HAM-D) Score
The Hamilton Depression Rating Scale (HAMD-24) is a clinician-administered 24-item scale used to assess the severity of depressive symptoms. Most items are scored on a 5-point scale (0 = absent to 4 = very severe), with some items scored on a 3-point scale (0 = absent to 2 = severe). Total score ranges from 0 to approximately 76, with higher scores indicating greater severity of depression. The scale is administered by trained clinicians. Change = (Week 4 or Week 8 total score - Baseline total score). Negative changes indicate improvement (reduction) in depressive symptoms.
Time frame: Baseline, Week 4, and Week 8
Change From Baseline in SF-36 Physical Component Summary (PCS) Score
The SF-36 is a validated 36-item self-reported questionnaire that assesses health-related quality of life across 8 domains (scores 0-100, higher = better). The Physical Component Summary (PCS) is a norm-based summary score derived from weighted factor analysis of the 8 domains, standardized to a general population mean of 50 and standard deviation of 10 (higher scores indicate better physical health-related quality of life). Chinese mainland adapted version (validated by Li et al., Zhejiang University, Hangzhou community norms) used. Change = (Week 4 or Week 8 PCS score - Baseline PCS score). Positive changes indicate improvement in physical health-related quality of life. Administered via self-report with guidance from study personnel.
Time frame: Baseline, Week 4, and Week 8
Change From Baseline in SF-36 Mental Component Summary (MCS) Score
The SF-36 is a validated 36-item self-reported questionnaire that assesses health-related quality of life across 8 domains (scores 0-100, higher = better). The Mental Component Summary (MCS) is a norm-based summary score derived from weighted factor analysis of the 8 domains, standardized to a general population mean of 50 and standard deviation of 10 (higher scores indicate better mental health-related quality of life). Chinese mainland adapted version (validated by Li et al., Zhejiang University, Hangzhou community norms) used. Change = (Week 4 or Week 8 MCS score - Baseline MCS score). Positive changes indicate improvement in mental health-related quality of life. Administered via self-report with guidance from study personnel.
Time frame: Baseline, Week 4, and Week 8
Incidence of Major Adverse Cardiovascular Events (MACE) Within 8 Weeks of Treatment
Major Adverse Cardiovascular Events (MACE) is a composite safety endpoint defined as the occurrence of any of the following events during the 8-week treatment period: Cardiovascular death Non-fatal myocardial infarction (MI) Non-fatal stroke Hospitalization for unstable angina requiring urgent revascularization Other protocol-defined major cardiovascular events (if applicable, e.g., severe heart failure exacerbation or resuscitated cardiac arrest) The incidence rate is calculated as the proportion of participants experiencing at least one MACE event (number of participants with ≥1 event / total number of participants in the analysis population × 100%). Events are adjudicated by an independent clinical events committee (if applicable) or by the investigator based on clinical records, ECG, biomarkers, and imaging. This outcome is assessed for safety monitoring and exploratory comparison between treatment arms.
Time frame: From randomization (baseline) through Week 8 (end of treatment period)
Vital Signs (Body Temperature)
Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Body temperature (°C) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.
Time frame: Baseline, Week 8
Vital Signs (Pulse Rate)
Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Pulse rate (beats per minute, bpm) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.
Time frame: Baseline, Week 8
Vital Signs (Respiratory Rate)
Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Respiratory rate (breaths per minute) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.
Time frame: Baseline, Week 8
Vital Signs (Blood Pressure)
Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Blood pressure (systolic and diastolic, mmHg) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) are recorded and reported separately.
Time frame: Baseline, Week 8
Laboratory Parameters (Hematology-Red Blood Cell count)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Red Blood Cell count (RBC) Unit: ×10¹²/L (Number of red blood cells per liter of blood × 10¹²) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Hematology-White Blood Cell count)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): White Blood Cell count (WBC) Unit: ×10⁹/L (Number of white blood cells per liter of blood × 10⁹) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Hematology- Platelet count)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Platelet count (PLT) Unit: ×10⁹/L (Number of platelets per liter of blood × 10⁹) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Hematology-Hemoglobin )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Hemoglobin (Hb)-Hemoglobin Concentration Unit: g/L (grams per liter) or g/dL All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Liver Function-Alanine Aminotransferase)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Alanine Aminotransferase (ALT) Unit: U/L (units per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Liver Function- Aspartate Aminotransferase)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Aspartate Aminotransferase (AST) Unit: U/L (units per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Liver Function-Total Bilirubin)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Total Bilirubin (TBIL) Unit: μmol/L (micromoles per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Liver Function-Alkaline Phosphatase)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function:Alkaline Phosphatase (ALP) Unit: U/L (units per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Renal Function- Serum Creatinine )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Serum Creatinine (Scr) Unit: μmol/L (micromoles per liter) or mg/dL All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Urinalysis-Protein )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Protein (PRO) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mg/dL, g/L) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Urinalysis-Glucose )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Glucose (GLU) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mmol/L, mg/dL) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Urinalysis-Erythrocytes)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Erythrocytes (ERY) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Laboratory Parameters (Urinalysis-Leukocytes)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Leukocytes (LEU) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.
Time frame: Baseline, Week 8
Heart Rate on 12-lead electrocardiogram
Heart rate (beats per minute) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Used for cardiac safety monitoring. Clinically significant changes are reported as adverse events. Unit of Measure: beats per minute (bpm)
Time frame: Baseline, Week 4, Week 8
PR Interval on 12-lead electrocardiogram
PR interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Assessed as part of cardiac conduction safety evaluation. Clinically significant prolongation is reported as an adverse event. Unit of Measure: milliseconds (ms)
Time frame: Baseline, Week 4, Week 8
QRS Duration on 12-lead electrocardiogram
QRS duration (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Monitored for potential ventricular conduction abnormalities. Clinically significant changes are reported as adverse events. Unit of Measure: milliseconds (ms)
Time frame: Baseline, Week 4, Week 8
QT Interval on 12-lead electrocardiogram
QT interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Used for cardiac repolarization safety assessment. Unit of Measure: milliseconds (ms)
Time frame: Baseline, Week 4, Week 8
Corrected QT Interval (QTc) on 12-lead electrocardiogram
Corrected QT interval (QTc, milliseconds) is calculated from the QT interval on a standard 12-lead electrocardiogram (recorded after ≥5 minutes rest, supine position, calibrated equipment) using Bazett or Fridericia formula as specified in the protocol. Interpreted by qualified cardiologists or trained investigators. QTc prolongation (e.g., \>500 ms) is considered clinically significant and reported as an adverse event. Key cardiac safety parameter. Unit of Measure: milliseconds (ms)
Time frame: Baseline, Week 4, Week 8
"Shang Huo" (Excess Heat) Symptoms Score
"Shang Huo" often translated as excess internal heat or fire syndrome in Traditional Chinese Medicine. Key symptoms include: Dry mouth / thirst; Oral ulcers or sores on tongue/mouth; Swollen and painful gums; Increased appetite with easy hunger; Constipation; Other possible accompanying symptoms (e.g., sore throat, red eyes, irritability, if protocol-defined).
Time frame: Baseline, Week 4, Week 8, Week 12
Incidence, Severity, Timing, and Relationship of Adverse Events (AEs)
Adverse events will be evaluated in terms of type, incidence, severity, time of onset, and relationship to the study drug. Types of adverse events are classified as: Adverse Event (AE), Serious Adverse Event (SAE), and Suspected Unexpected Serious Adverse Reaction (SUSAR). Severity is graded as: mild, moderate, or severe. Mild: The subject can tolerate the event; it does not interfere with ongoing treatment, requires no special intervention, and has no impact on the subject's recovery. Moderate: The subject finds the event difficult to tolerate; it necessitates discontinuation of the study drug or special treatment, and it directly affects the subject's recovery. Severe: The event is life-threatening, results in death or permanent disability/incapacity, and requires immediate discontinuation of the study drug or emergency intervention.
Time frame: Week 4, Week 8, Week 12/EOS/EOT
Pharmacokinetic (PK) Parameters-Plasma Maximum Observed Concentration (Cmax)
Plasma concentration measured from blood samples collected opportunistically at Week 4 (or Week 8/early discontinuation). Cmax is the maximum observed concentration post-dose. Parameters estimated using non-compartmental analysis or population PK modeling due to sparse sampling. Geometric mean and variability reported. Assessed as an exploratory pharmacokinetic biomarker. Unit of Measure: ng/mL (or appropriate unit, e.g., nmol/L)
Time frame: Baseline, Week 4, Week 8
Pharmacokinetic (PK) Parameters-Plasma Trough Concentration (Ctrough)
Blood samples collected opportunistically at Week 4 and at Week 8 (or early termination), ideally at pre-dose timing where possible. Plasma concentration of \[Drug Name\] measured using validated bioanalytical methods. Ctrough is the observed minimum concentration at the end of the dosing interval. Reported as geometric mean and variability. Exploratory pharmacokinetic endpoint focusing on steady-state trough exposure. Unit of Measure: ng/mL (or nmol/L, adjust based on drug)
Time frame: Baseline, Week 4, Week 8
Pharmacokinetic (PK) Parameters-Time Curve (AUC0-last)
Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-last) , estimated from sparse opportunistic sampling at Week 4 (or Week 8) using population PK methods. Geometric mean reported. Exploratory PK biomarker of exposure. Unit of Measure: h·ng/mL (or appropriate, e.g., h·nmol/L
Time frame: Baseline, Week 4, Week 8
Fecal Multi-Omics Profile
Fecal samples collected at baseline and Week 8 . Multi-omics analysis (including gut microbiome profiling via 16S rRNA sequencing or metagenomics, and fecal metabolomics via targeted/untargeted methods) performed to assess overall changes in microbial composition, diversity, and metabolic products (e.g., short-chain fatty acids and other microbial-derived metabolites). Changes from baseline evaluated as exploratory biomarkers of treatment effects on gut microbiota and related metabolic pathways. Unit of Measure: Varies by assay (e.g., relative abundance %, μmol/g feces, diversity indices)
Time frame: Baseline, Week 8
Plasma Multi-Omics Profile
Blood samples collected at baseline, Week 4 (opportunistic sampling), and Week 8. Multi-omics analysis (including targeted/untargeted metabolomics and proteomics) performed on plasma to assess systemic changes in metabolites (e.g., tryptophan pathway intermediates) and proteins (e.g., inflammatory markers or neurotrophic factors). Changes from baseline evaluated as exploratory biomarkers of treatment effects on systemic metabolism and inflammation. Unit of Measure: Varies by assay (e.g., nmol/L or pg/mL)
Time frame: Baseline, Week 4, Week 8
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.
Of 16 phase 2 interventional studies under Myocardial Ischemia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Longhua Hospital